The DOI matches its Crossref record; 43 of the 46 references it cites were found in a registry or an index.
Risk of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials
Open accessAbstract
Purpose To describe risk factors for geographic atrophy (GA) in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).Design Cohort within a randomized clinical trial.Participants We analyzed 1024 CATT patients with no GA visible on color fundus photographs (CFPs) and/or fluorescein angiograms (FAs) at enrollment.Methods Eyes were assigned to ranibizumab (0.5 mg) or bevacizumab (1.25 mg) treatment and to a 2-year monthly or pro re nata (PRN) injection regimen, or monthly injections for 1 year and PRN for 1 year. Demographic, genetic, and baseline ocular characteristics and lesion features of CFP/FA and optical coherence tomography (OCT) were evaluated as risk factors for GA through 2 years of follow-up. Time-dependent Cox proportional hazard models were used to estimate adjusted hazard ratios (aHRs).Main outcome measures Development of GA.Results By 2 years, GA developed in 187 of 1024 patients (18.3%). Baseline risk factors for GA development included baseline visual acuity (VA) ≤20/200 (aHR, 2.65; 95% confidence interval [CI], 1.43-4.93), retinal angiomatous proliferation (RAP; aHR, 1.69; 95% CI, 1.16-2.47), GA in the fellow eye (aHR, 2.07; 95% CI, 1.40-3.08), and intraretinal fluid at the foveal center (aHR, 2.10; 95% CI, 1.34-3.31). Baseline factors associated with lower risk for GA development included blocked fluorescence (aHR, 0.49; 95% CI, 0.29-0.82), OCT measurements of subretinal fluid thickness of >25 μ (aHR, 0.52; 95% CI, 0.35-0.78), subretinal tissue complex thickness of >275 compared with ≤75 μ (aHR, 0.31; 95% CI, 0.19-0.50), and vitreomacular attachment (aHR, 0.55; 95% CI, 0.31-0.97). Ranibizumab compared with bevacizumab had a higher risk (aHR, 1.43; 95% CI, 1.06-1.93), and monthly dosing had a higher risk (aHR, 1.59; 95% CI, 1.17-2.16) than PRN dosing. There were no strong associations between development of GA and the presence of risk alleles for CFH, ARMS 2, HTRA1, C3, or TLR3.Conclusions Approximately one fifth of CATT patients developed GA within 2 years of treatment. Independent baseline risk factors included poor VA, RAP, foveal intraretinal fluid, monthly dosing, and treatment with ranibizumab. Anti-vascular endothelial growth factor therapy may have a role in the development of GA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Unfortunately, up to 30% of patients can still have intraretinal fluid with vision loss after 1 year of therapy [2–4].”
From Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients (2024) · cites this paper as [4]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Prevalence of Age-Related Macular Degeneration in the United States
The Eye Diseases Prevalence Research Group* (2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.564 · Cited by 2,774
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715
Self-citationIntravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration
Avery, R. L., Pieramici, D. J., Rabena, M., CASTELLARIN, A. A., Nasir, M. A., & Giust, M. J. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2005.11.019 · Cited by 1,134
Rosenfeld, P. J., Moshfeghi, A. A., & Puliafito, C. A. (2005) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/1542-8877-20050701-14 · Cited by 912
Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Culliford, L. A., & Reeves, B. C. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61501-9 · Cited by 748
Relationship between RPE and Choriocapillaris in Age-Related Macular Degeneration
McLeod, D. S., Grebe, R. R., Bhutto, I. A., Merges, C. A., Baba, T., & Lutty, G. A. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-3639 · Cited by 568
Cited by
Sorted by citations
Items 401–500 of 586
Oliveira, M., Farinha, C., Rodrigues, T. M., Martins, A., Cachulo, M. L., Marques, J. P., Pires, I., & da Silva, R. M. (2020) · European Journal of Ophthalmology · doi:10.1177/1120672120908718 · Cited by 7
Rispoli, M., Savastano, M. C., Lumbroso, B. D., Toto, L., & Antonio, L. D. (2020) · BioMed Research International · doi:10.1155/2020/4501395 · Cited by 7
Richert, E., von der Burchard, C. C., Klettner, A., Arnold, P., Lucius, R., Brinkmann, R., Roider, J. B., & Tode, J. (2020) · Cytokine X · doi:10.1016/j.cytox.2020.100031 · Cited by 7
Chan, C. K., Sarraf, D., Abraham, P., Lalezary, M., LIN, S. G., Chen, X., Nittala, M. G., & Sadda, S. R. (2020) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2020.100916 · Cited by 7
Hu, S., Chen, Y., Xie, D., Xu, K., Fu, Y., Chi, W., Liu, H., & Huang, J. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1383 · Cited by 8
Self-citationAtrofia geográfica: etiopatogenia y terapias actuales
Sastre-Ibáñez, M., Barreiro-González, A., Gallego‐Pinazo, R., Dolz‐Marco, R., & Armendariz, B. G. (2017) · Archivos de la Sociedad Española de Oftalmología · doi:10.1016/j.oftal.2017.07.004 · Cited by 7
Scoles, D., Ying, G., Pan, W., Hua, P., Grunwald, J. E., Daniel, E., Jaffe, G. J., Toth, C. A., Martin, D. F., & Maguire, M. G. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2019.5831 · Cited by 7
Self-citationKim, K. T., Lee, H., Kim, J. Y., Lee, S., Chae, J. B., & Kim, D. Y. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061863 · Cited by 7
Zhang, P., Wang, H., Cao, H., Xu, X., & Sun, T. (2017) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2016.0171 · Cited by 7
Kim, J. H., Chang, Y. S., Kim, J. W., Kim, C. G., & Lee, D. W. (2019) · International Journal of Ophthalmology · doi:10.18240/ijo.2019.03.20 · Cited by 7
Systemic changes in neovascular age-related macular degeneration.
Singh, A. (2014) · PubMed · Cited by 7
Chong Teo, K. Y., Nguyen, V., Gemmy Cheung, C. M., Arnold, J., Chen, F. K., Barthelmes, D., & Gillies, M. C. (2021) · Zurich Open Repository and Archive (University of Zurich) · doi:10.1097/iae.0000000000003267 · Cited by 6
Jaffe, G. J., Cameron, B., Barteselli, G., Callaway, N. F., Skalak, C., Choong, J., & Gune, S. (2025) · Ophthalmology Retina · doi:10.1016/j.oret.2025.02.017 · Cited by 6
Self-citationJaffe, G. J., Cameron, B., Kardatzke, D. R., Ives, J. A. L., Barteselli, G., & Gune, S. (2022) · Ophthalmology Retina · doi:10.1016/j.oret.2022.04.006 · Cited by 6
Self-citationSustained Suppression of VEGF for Treatment of Retinal and Choroidal Vascular Diseases
Campochiaro, P. A. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.04.032 · Cited by 6
Narrative review-drug delivery in age-related macular degeneration
Israilevich, R. N., Mahmoudzadeh, R., Salabati, M., & Xu, D. N. (2021) · Annals of Eye Science · doi:10.21037/aes-21-8 · Cited by 6
Kim, D., Yoon, C. K., & Yu, H. G. (2021) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2021.10.033 · Cited by 6
Sotani, R., Matsumiya, W., Kim, K. W., Miki, A., Yasuda, E., Maeda, Y., Hara, R., Kusuhara, S., & Nakamura, M. (2023) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-023-06036-x · Cited by 6
Kim, J. H., Kim, J. W., & Kim, C. G. (2023) · Retina · doi:10.1097/iae.0000000000003797 · Cited by 6
Ma, H., Wei, H., Zou, C., Zhu, G., Gao, Q., Zhang, N., & Wang, B. (2023) · Drugs & Aging · doi:10.1007/s40266-023-01068-8 · Cited by 6
Ranibizumab: A Review of its Use in Myopic Choroidal Neovascularization
Deeks, E. D. (2014) · BioDrugs · doi:10.1007/s40259-014-0102-5 · Cited by 6
Gene therapy for age-related macular degeneration
MacLaren, R. E. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00346-3 · Cited by 6
Intravitreal topotecan inhibits laser-induced choroidal neovascularization in a rat model
Kanavi, M., Gholipour, M., Ahmadieh, H., Aldavood, S. J., Nourinia, R., Hosseini, S., Daftarian, N., Nashtaei, E. M., Tousi, A., & Safi, S. (2015) · Journal of Ophthalmic and Vision Research · doi:10.4103/2008-322x.170339 · Cited by 6
Oellers, P. R., Grewal, D. S., & Fekrat, S. (2016) · Clinical ophthalmology · doi:10.2147/opth.s98853 · Cited by 6
Geographic atrophy: Etiopathogenesis and current therapies
Sastre-Ibáñez, M., Barreiro-González, A., Gallego‐Pinazo, R., Dolz‐Marco, R., & Armendariz, B. G. (2017) · Archivos de la Sociedad Española de Oftalmología (English Edition) · doi:10.1016/j.oftale.2017.10.003 · Cited by 6
The current role of steroids in diabetic macular edema
Cicinelli, M. V., Cavalleri, M., Lattanzio, R., & Bandello, F. M. (2020) · Expert Review of Ophthalmology · doi:10.1080/17469899.2020.1729743 · Cited by 6
Nguyen, V., Puzo, M., Sánchez‐Monroy, J., Gabrielle, P., Creuzot-Garcher, C. P., Baudin, F., Wolff, B., Castelnovo, L., Michel, G., O’Toole, L., et al. (2020) · Retina · doi:10.1097/iae.0000000000003061 · Cited by 6
Vottonen, P. (2018) · Acta Ophthalmologica · doi:10.1111/aos.13706 · Cited by 6
Choi, E. Y., Park, S. E., Lee, S. C., Koh, H. J., Kim, S. S., Byeon, S. H., Kim, M., & Lee, C. S. (2019) · Ophthalmologica · doi:10.1159/000501724 · Cited by 6
Detaram, H. D., Liew, G., Russell, J. C., Vu, K. V., Burlutsky, G., Mitchell, P. L. R., & Gopinath, B. (2020) · Acta Ophthalmologica · doi:10.1111/aos.14394 · Cited by 6
Razavi, H., Arnold, J., & Guymer, R. H. (2015) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.12658 · Cited by 6
C3 Function and Inhibition in Geographic Atrophy: Interesting Insights from a Phase 2 Study
Wong, W. T. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.09.008 · Cited by 6
Thalgott, V., Feucht, N., Cp, L., & Maier, M. M. (2016) · PubMed · doi:10.1007/s00347-016-0228-6 · Cited by 5
Moraes, G., Struyven, R., Wagner, S. K., Liu, T., Chong, D., Abbas, A., Chopra, R., Patel, P. J., Balaskas, K., Keenan, T. D. L., et al. (2024) · Ophthalmology Science · doi:10.1016/j.xops.2024.100570 · Cited by 6
Wada, I., Oshima, Y., Fukuda, Y., Shiose, S., Kano, K., Ishikawa, K., Nakao, S., Kaizu, Y., Hasegawa, E., Kannan, R., et al. (2025) · Clinical ophthalmology · doi:10.2147/opth.s501953 · Cited by 5
Cabral, D., Coscas, F., Pereira, T., Laiginhas, R., Rodrigues, C., Français, C., Nogueira, V., Falcão, M. S., Mière, A., Lupidi, M., et al. (2020) · Retina · doi:10.1097/iae.0000000000002842 · Cited by 5
End binding-3 inhibitor activates regenerative program in age-related macular degeneration
Lee, Q. S., Chan, W. C., Qu, X., Sun, Y., Abdelkarim, H., Le, J., Saqib, U., Sun, M., Kruse, K. J., Banerjee, A., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101223 · Cited by 5
Nanoparticles Targeting Retinal and Choroidal Capillaries In Vivo
Haunberger, A., & Göpferich, A. M. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8669-9_25 · Cited by 5
Ahn, S. J., Lee, H., Hong, H. K., Jung, J. H., Park, J. H., Park, K. H., Kim, S. E., Woo, S. J., & Lee, B. C. (2018) · Molecular Imaging and Biology · doi:10.1007/s11307-018-1294-8 · Cited by 5
One-Year Results of Fixed Aflibercept Treatment Regime in Type 3 Neovascularization
Ernest, J., Manethová, K., Kolář, P., Sobíšek, L., Sacconi, R., & Querques, G. (2019) · Ophthalmologica · doi:10.1159/000499719 · Cited by 5
Hosogi, M., Morizane, Y., Shiode, Y., Doi, S., Kumase, F., Kimura, S., Hosokawa, M. M., Hirano, M., Toshima, S., Takahashi, K., et al. (2018) · PubMed · doi:10.18926/amo/55661 · Cited by 5
Casalino, G., Arrigo, A., Introini, U., Scialdone, A., Coppola, M., Bandello, F. M., Chakravarthy, U., & Parodi, M. B. (2020) · Current Eye Research · doi:10.1080/02713683.2020.1849730 · Cited by 5
Novais, E. A., Badaró, E., Hirai, F. E., Jorge, F. A., Leal, P., Farah, M. E., & Rodrigues, E. B. (2016) · Journal of Ophthalmology · doi:10.1155/2016/6971831 · Cited by 5
Intravitreal aflibercept for choroidal neovascularisation in angioid streaks
Vaz-Pereira, S., Collaço, L., Salvo, G. D., & van Zeller, P. (2016) · Eye · doi:10.1038/eye.2015.284 · Cited by 5
Sorenson, C. M., Gurel, Z., Song, Y.-S., Peterson, K. D., Blodi, B. A., & Sheibani, N. (2024) · PLOS ONE · doi:10.1371/journal.pone.0297135 · Cited by 5
Self-citationMultiomics data reveal microglia's promotion for choroidal neovascularization in endothelial cells
Li, H., Dong, L., Shao, L., & Wei, W. (2025) · Experimental Eye Research · doi:10.1016/j.exer.2025.110701 · Cited by 4
Kantor, A. B., Rickert, M., Cheng, H., Flanagan, K., Salgotra, V., Suppahia, A., Ryu, J. K., Widboom, P., Warfield, J. R., Akassoglou, K., et al. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03650-w · Cited by 5
Blazaki, S. V., Blavakis, E., CHLOUVERAKIS, G. I., Bontzos, G., Chatziralli, I., Smoustopoulos, G., Dimitriou, E., Stavrakakis, A., Kabanarou, S. A., Xirou, T., et al. (2023) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-023-06168-0 · Cited by 4
Lee, J. H., Shin, J. Y., & Ahn, J. (2024) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-024-01134-7 · Cited by 4
Type 3 Macular Neovascularization in Age-related Macular Degeneration
Sacconi, R., Forte, P., Corradetti, G., Costanzo, E., Capuano, V., Bousquet, E., Beretta, F., Iannuzzi, S., Polito, M. S., Nicolò, M., et al. (2024) · Ophthalmology Retina · doi:10.1016/j.oret.2024.11.011 · Cited by 4
Makarczyk, L. D. S. Q., Ugarte, M. D. F. S., Vieira, B. V., Kniggendorf, S. L., & Regatieri, C. V. (2020) · International Journal of Retina and Vitreous · doi:10.1186/s40942-020-00212-5 · Cited by 4
Yuan, Y., Kong, W., Liu, X., & Shi, G. (2022) · Current Gene Therapy · doi:10.2174/1566523222666220405135135 · Cited by 4
Nakai, A., Lee, D., Shoda, C., Negishi, K., Nakashizuka, H., Yamagami, S., & Kurihara, T. (2023) · Journal of Ophthalmology · doi:10.1155/2023/6617981 · Cited by 4
Takagi, S. T., Mandai, M., Miyamoto, N., Nishida, A., Hirami, Y., Uyama, H., Yamamoto, M., Takahashi, M., Tomita, G., & Kurimoto, Y. (2017) · Clinical ophthalmology · doi:10.2147/opth.s134338 · Cited by 4
Takahashi, H., Inoue, Y., Tan, X., Inoda, S., Sakamoto, S., Arai, Y., Yanagi, Y., Fujino, Y., & Kawashima, H. (2018) · Clinical ophthalmology · doi:10.2147/opth.s151999 · Cited by 4
The role of anti-VEGF therapy in geographic atrophy progression
Plyukhova, A. A., & Budzinskaya, M. V. (2018) · Russian Annals of Ophthalmology · doi:10.17116/oftalma2018134051289 · Cited by 5
Taipale, C., Laine, I., & Tuuminen, R. (2018) · Clinical ophthalmology · doi:10.2147/opth.s188624 · Cited by 5
Posterior vitreous detachment rate following intravitreal dexamethasone injection
Alpay, A. (2019) · International Journal of Ophthalmology · doi:10.18240/ijo.2019.08.10 · Cited by 5
Keleş, A. (2021) · Beyoglu Eye Journal · doi:10.14744/bej.2021.49140 · Cited by 4
Yasukawa, T., Mori, R., Sawa, M., Shinojima, A., Hara, C., Sekiryu, T., Oshima, Y., Saito, M., Sugano, Y., Kato, A., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213161 · Cited by 4
Asahi, M., Wallsh, J. O., Onishi, S., Kuroyama, S., & Gallemore, R. P. (2020) · Clinical ophthalmology · doi:10.2147/opth.s270243 · Cited by 4
Nassisi, M., & Sadda, S. R. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-66014-7_2 · Cited by 4
Loukianou, E., Brοuzas, D., CHATZISTEFANOU, K. I., & Koutsandrea, C. (2015) · International Ophthalmology · doi:10.1007/s10792-015-0066-6 · Cited by 4
Ono, A., Shiragami, C., Manabe, S., Takasago, Y., Osaka, R., Kobayashi, M., Yamashita, A., Tsujikawa, A., & Hirooka, K. (2018) · Medicine · doi:10.1097/md.0000000000011737 · Cited by 4
Karaçorlu, M., Hocaoğlu, M., Arf, S., Ersöz, M. G., & Muslubaş, I. S. (2019) · Turkish Journal of Ophthalmology · doi:10.4274/tjo.galenos.2019.26235 · Cited by 4
Sophie, R., Wang, J., & Campochiaro, P. A. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.12.043 · Cited by 4
Management of fibrosis in neovascular age-related macular degeneration
Chakravarthy, U., Foss, A. J. E., Panos, G. D., Pető, T., Rotsos, T., Sadda, S. R., Cock, E. D., & Empeslidis, T. (2025) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-025-06890-x · Cited by 3
Parimi, V., Elsner, A. E., Papay, J. A., Clark, C. A., Miura, M., & Gast, T. J. (2024) · Ophthalmic and Physiological Optics · doi:10.1111/opo.13422 · Cited by 3
Kolomeyer, A. M., Smith, E. J., Daniel, E., Ying, G., Pan, W., Pistilli, M., Grunwald, J. E., Maguire, M. G., & Kim, B. J. (2020) · Retina · doi:10.1097/iae.0000000000002825 · Cited by 3
Self-citationWilde, C., Poostchi, A., Hillman, J. G., MacNab, H. K., Vernon, S. A., & Amoaku, W. M. K. (2020) · Eye · doi:10.1038/s41433-020-01169-3 · Cited by 3
Ji, M. H., Callaway, N. F., Ludwig, C. A., Vail, D. G., Al‐Moujahed, A., Rosenblatt, T. R., Leng, T., Sanislo, S. R., & Moshfeghi, D. M. (2021) · European Journal of Ophthalmology · doi:10.1177/11206721211001708 · Cited by 3
Functional and anatomical outcomes of brolucizumab for nAMD in a real-life setting
Pastore, M. R., Milan, S., Cirigliano, G., & Tognetto, D. (2024) · Scientific Reports · doi:10.1038/s41598-024-51315-0 · Cited by 3
The influence of hyperglycemia on the safety of ultrasound in retinal pigment epithelial cells
Kang, H., Yin, N., Lyon, H., Rupenthal, I. D., Thakur, S. S., & Mugisho, O. O. (2020) · Cell Biology International · doi:10.1002/cbin.11477 · Cited by 3
Laser Therapy Versus Anti-VEGF Agents for Treatment of Retinopathy of Prematurity
Leskov, I. B., & Mukai, S. (2015) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000090 · Cited by 3
Marques, M. F., Marques, J. P., Gil, J., Costa, J. C., Almeida, E., Cachulo, M. L., Pires, I., Figueira, J., & da Silva, R. M. (2015) · Ophthalmic Research · doi:10.1159/000441797 · Cited by 3
Acar, U., Acar, D. E., Pınarlı, F. A., Demir, M. N., Beyazyıldız, E., Özdemir, Ö., Sevim, D. G., Tiryaki, M., & Sobacı, G. (2016) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.12715 · Cited by 3
Ranjbar, M., Kurz, M., Holzhey, A., Rades, D., & Grisanti, S. (2017) · Current Eye Research · doi:10.1080/02713683.2017.1355972 · Cited by 3
State of the art management of diabetic macular edema
Nourinia, R. (2015) · World Journal of Ophthalmology · doi:10.5318/wjo.v5.i2.55 · Cited by 3
Park, Y. J., Son, G. S., Kim, Y. J., Kim, J.-G., Yoon, Y. H., & Lee, J. Y. (2018) · Journal of the Korean Ophthalmological Society · doi:10.3341/jkos.2018.59.12.1142 · Cited by 3
Toto, L., Viggiano, P., Quarta, A., Grassi, M. O., Nicola, C. D., Aloia, R., D’Aloisio, R., Boscia, G., Boscia, F., Porreca, A., et al. (2024) · Ophthalmic Research · doi:10.1159/000538441 · Cited by 2
Konukcu, O., Argun, M., Acer, S., Çelik, Ö., Tök, L., Tök, L., & Nazıroğlu, M. (2026) · Biomolecules · doi:10.3390/biom16060883 · Cited by 2
Vofo, B. N., Shwartz, Y., Cnaany, Y., Jaskoll, S., Kramer, A., Elbaz-Hayoun, S., Rinsky, B., Grunin, M. A., Tiosano, L., & Chowers, I. (2025) · Eye · doi:10.1038/s41433-025-03723-3 · Cited by 2
Mehta, N. N., Nagel, I. D., Agnihotri, A. P., Kalaw, F. G. P., Heinke, A., Cheng, L., Bartsch, D., & Freeman, W. R. (2025) · British Journal of Ophthalmology · doi:10.1136/bjo-2024-326124 · Cited by 2
Ota, H., Takeuchi, J., Nonogaki, R., Tamura, K., Kaneko, H., & Nishiguchi, K. M. (2025) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-025-01224-0 · Cited by 2
OUTCOMES OF TREAT-AND-EXTEND USING AFLIBERCEPT IN TYPE 3 MACULAR NEOVASCULARIZATION
Kim, J. H., Kim, Y., Park, S. M., & Cho, H. J. (2025) · Retina · doi:10.1097/iae.0000000000004571 · Cited by 2
Zang, X., Zhang, L., Ma, J., Wang, A., Ding, L., Wang, Y., Sun, J., Li, J., Hang, X., Li, X., et al. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s505055 · Cited by 2
Borrelli, E., Bandello, F. M., Bhutto, I. A., Reibaldi, M., & Edwards, M. M. (2026) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2026.101475 · Cited by 2
Olivieri, C., Perin, G., Zhuang, X., Neri, G., Parisi, G., Marolo, P., Viggiano, P., Boscia, F., Reibaldi, M., & Borrelli, E. (2026) · Ophthalmology Science · doi:10.1016/j.xops.2026.101268 · Cited by 2
Salcedo-Villanueva, G., Harasawa, M., Vélez-Montoya, R., Mathias, M. T., Siringo, F. S., Olson, J. L., Oliver, S. C. N., Mandava, N., & Quiroz–Mercado, H. (2014) · Retina · doi:10.1097/iae.0000000000000373 · Cited by 2
Yuan, Y., Kong, W., Liu, X., & Shi, G. (2023) · Current Medical Science · doi:10.1007/s11596-022-2684-3 · Cited by 2
Therapeutic targeting of telomerase ameliorates experimental choroidal neovascularization
Kumar, A., Nagasaka, Y., Jayananthan, V., Zidan, A. A., Heisler‐Taylor, T., Ambati, J., Tamiya, S., & Kerur, N. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167156 · Cited by 2
Hashimoto, Y., Hunt, A., Wells, J. M., Banerjee, G., Ferrier, R., Barry, R., Field, A., Game, J. A., Hooper, C., Barthelmes, D., et al. (2024) · British Journal of Ophthalmology · doi:10.1136/bjo-2024-326024 · Cited by 2
Ueda‐Consolvo, T., Shibuya, N., Oiwake, T., Abe, S., Numata, A., Honda, Y., Yanagisawa, S., & Hayashi, A. (2021) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-021-05270-5 · Cited by 2
Sarwar, S., Sadiq, M. A., Hanout, M., & Nguyen, Q. D. (2015) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-015-3146-4 · Cited by 2
Gallego‐Pinazo, R., Figueroa, M. S., & García‐Layana, A. (2015) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000151 · Cited by 2
Response-based individualized medicine for neovascular age-related macular degeneration
Yasukawa, T. (2015) · Expert Review of Ophthalmology · doi:10.1586/17469899.2015.1019473 · Cited by 2
Garweg, J. G. (2016) · Der Ophthalmologe · Cited by 2
Biomaterials for intraocular sustained drug delivery
Yasukawa, T. (2016) · Elsevier eBooks · doi:10.1016/b978-0-08-100147-9.00006-7 · Cited by 2
Ashraf, M., Souka, A., & Adelman, R. A. (2016) · Retina · doi:10.1097/iae.0000000000001423 · Cited by 2
New Frontiers of Retinal Therapeutic Innovation & Strategic Insights
Qiu, T. G., & Laties, A. M. (2015) · Cited by 2
Metadata
- Authors
- Grunwald, J. E., Daniel, E., Huang, J., Ying, G.-S., Maguire, M. G., Toth, C. A., Jaffe, G. J., Fine, S. L., Blodi, B., Klein, M. L., Martin, A. A., Hagstrom, S. A., & Martin, D. F.
- Affiliations
- University of Pennsylvania (US)
- Duke University (US)
- University of Colorado Anschutz (US)
- University of Wisconsin–Madison (US)
- Oregon Health & Science University (US)
- Cleveland Clinic (US)
- Corresponding author
- Grunwald, Juan E.
- ORCID
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2014-01
- Volume
- 121
- Issue
- 1
- Pages
- 150-161
- ISSN
- 0161-6420 (ISSN-L)
- PMC
- PMC3892560
- OpenAlex
- W2131192872
- Cited by
- 590
- References
- 46
- Citations by year
- 2026: 17 · 2025: 30 · 2024: 33 · 2023: 26 · 2022: 32 · 2021: 45 · 2020: 68 · 2019: 55 · 2018: 48 · 2017: 57 · 2016: 79 · 2015: 70 · 2014: 30
- FWCI
- 58.79
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Ophthalmology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Eye Institute (U10 EY017823, U10 EY017825, U10 EY017826, and U10 EY017828)
- National Institutes of Health
- Department of Health and Human Services
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- geographic atrophy, age-related macular degeneration, risk factors, ranibizumab, bevacizumab, anti-VEGF therapy, intravitreal injection, retinal angiomatous proliferation, subretinal fluid, visual acuity, choroidal neovascularization, retinal pigment epithelium
- MeSH terms
- Bevacizumab, Ranibizumab, Aged, Aged, 80 and over, Female, Fluorescein Angiography, Follow-Up Studies, Humans, Male, Middle Aged, Risk Factors, Visual Acuity, Cohort Studies, Incidence, Proportional Hazards Models, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Geographic Atrophy, Wet Macular Degeneration, Genotyping Techniques, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
